Nurse Practitioner in Star City, AR Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Leah Jacks Williams, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 110 N Drew, Star City, AR 71667 Phone: 870-628-5110 Fax: 870-628-5949 |
April Summer Mcghee, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 110 N Drew St, Star City, AR 71667 Phone: 870-628-5110 Fax: 855-854-6281 |
Mrs. Amy Michelle White, N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 110 N Drew St, Star City, AR 71667 Phone: 870-628-5110 Fax: 855-854-6281 |
Kendal Noble, APRN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 110 N Drew St, Star City, AR 71667 Phone: 870-628-5110 |
Holley Shelton, APN-NP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 110 N Drew, Star City, AR 71667 Phone: 870-628-5110 Fax: 870-854-6281 |
Kacee Reynolds, APRN Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 110 N Drew St, Star City, AR 71667 Phone: 870-628-5110 Fax: 855-854-6281 |
News Archive
SARS-CoV-2 D614G mutation associated with lower antibody binding
The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.
Microbe's multilayer defence mechanisms could treat fungal infections
Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.
Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3
Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3.
Surge of pediatric patients with diabetic ketoacidosis during COVID-19 pandemic
According to the Centers for Disease Control and Prevention (CDC), children generally appear to be less severely impacted by COVID-19 than adults.
Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated
Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.
› Verified 5 days ago